These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
906 related articles for article (PubMed ID: 20026770)
21. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380 [TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD; Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740 [TBL] [Abstract][Full Text] [Related]
23. Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38". Serebruany VL Circulation; 2010 Aug; 122(8):e436; author reply e437. PubMed ID: 20733108 [No Abstract] [Full Text] [Related]
24. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. Baker WL; White CM Am J Cardiovasc Drugs; 2009; 9(4):213-29. PubMed ID: 19655817 [TBL] [Abstract][Full Text] [Related]
25. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Ojeifo O; Wiviott SD; Antman EM; Murphy SA; Udell JA; Bates ER; Mega JL; Sabatine MS; O'Donoghue ML JACC Cardiovasc Interv; 2013 Dec; 6(12):1275-81. PubMed ID: 24239201 [TBL] [Abstract][Full Text] [Related]
26. Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. Salisbury AC; Wang K; Cohen DJ; Li Y; Jones PG; Spertus JA Circ Cardiovasc Qual Outcomes; 2013 Jan; 6(1):27-34. PubMed ID: 23212457 [TBL] [Abstract][Full Text] [Related]
27. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel? Wiviott SD Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Wiviott SD; Desai N; Murphy SA; Musumeci G; Ragosta M; Antman EM; Braunwald E Am J Cardiol; 2011 Oct; 108(7):905-11. PubMed ID: 21816379 [TBL] [Abstract][Full Text] [Related]
29. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122 [TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials. Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733 [TBL] [Abstract][Full Text] [Related]
31. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation. Panattoni L; Brown PM; Te Ao B; Webster M; Gladding P Pharmacoeconomics; 2012 Nov; 30(11):1067-84. PubMed ID: 22974536 [TBL] [Abstract][Full Text] [Related]
32. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E; Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851 [TBL] [Abstract][Full Text] [Related]
33. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Greenhalgh J; Bagust A; Boland A; Saborido CM; Fleeman N; McLeod C; Dundar Y; Dickson R; Proudlove C; Kolamunnage-Dona R; Fisher M Health Technol Assess; 2010 May; 14 Suppl 1():31-8. PubMed ID: 20507801 [TBL] [Abstract][Full Text] [Related]
34. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM; Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967 [TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Reese ES; Daniel Mullins C; Beitelshees AL; Onukwugha E Pharmacotherapy; 2012 Apr; 32(4):323-32. PubMed ID: 22461122 [TBL] [Abstract][Full Text] [Related]
36. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38). Udell JA; Braunwald E; Antman EM; Murphy SA; Montalescot G; Wiviott SD JACC Cardiovasc Interv; 2014 Jun; 7(6):604-12. PubMed ID: 24947719 [TBL] [Abstract][Full Text] [Related]
37. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. Motovska Z; Kala P Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914 [TBL] [Abstract][Full Text] [Related]
38. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. Cowper PA; Udayakumar K; Sketch MH; Peterson ED J Am Coll Cardiol; 2005 Feb; 45(3):369-76. PubMed ID: 15680714 [TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. De Servi S; Goedicke J; Schirmer A; Widimsky P Eur Heart J Acute Cardiovasc Care; 2014 Dec; 3(4):363-72. PubMed ID: 24818952 [TBL] [Abstract][Full Text] [Related]
40. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Lindgren P; Stenestrand U; Malmberg K; Jönsson B Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]